TNF Arthritis Treatment Grows, Sees Challengers; Humira to Dominate
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 12/05/11 -- Led by biologic therapies, the market for prescription treatments will exceed $20 billion in 2011, according to Kalorama Information. The healthcare market research publisher says that drugs that attack () led the market to 7.3% growth in revenues in 2010, and this type of growth is expected to continue, but not without challenges.
TNF is a type of cell death that leads to inflammation and is a main cause of arthritis pain. According to the report, products such as , or that can block TNF have been effective treatments and are leading in terms of revenue for the treatment of rheumatoid arthritis. Abbott's Humira leads the group of TNF products, but as the report's author suggests, the success of these products with rheumatologists and patients also means that it has become a competitive marketplace.
"Humira will likely become the world's biggest-selling drug by 2016, after the fall of Lipitor in 2011," said Melissa Elder, the report's author. "However, new products on the horizon and other factors may challenge this dominance over the next five years."
Entrants to this area include Bristol-Myers Squibb, with its recent introduction of Orencia, UCB with Cimzia and many others; so far the existing products have fended off those challenges. According to the report, some of the key factors that may challenge the dominance of treatments that attack TNF include new small molecule therapies that are attempting to vie for first-line utilization, the launch of biosimilars and physicians gaining comfort with IL-6 therapies; one or all of these could potentially derail the anti-TNF dominance.
The report notes that the prescription arthritis market is not without its challenges for all drug makers. Reimbursement for high-priced biologic medicines will be challenging over the next few years as payers seek to manage costs through purchasing arrangements and cost-sharing with their insured population, which could be a limiter to price growth, according to the report.
Kalorama Information's report, , has more information on this pharmaceutical market category including segmented market estimates, trends in the industry and detailed company profiles.
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on , and our .
Please direct all media inquiries to:
Bruce Carlson
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2011 - 17:20 Uhr
Sprache: Deutsch
News-ID 94071
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Information Services
Diese Pressemitteilung wurde bisher 300 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"TNF Arthritis Treatment Grows, Sees Challengers; Humira to Dominate"
steht unter der journalistisch-redaktionellen Verantwortung von
Kalorama Information (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
